Medios (XTRA:ILM1) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ILM1 Panoramica delle azioni

Medios AG, insieme alle sue controllate, fornisce specialità farmaceutiche principalmente in Germania.

ILM1 analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	4/6
Prestazioni passate	2/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Negoziato a 53.6% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 41.41% all'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Medios AG Concorrenti

HAEMATO

HMSE:HAEK

€85.2m

M1 Kliniken

XTRA:M12

€265.6m

RHÖN-KLINIKUM

XTRA:RHK

€783.2m

Stratec

XTRA:SBS

€531.8m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Medios
Prezzi storici delle azioni
Prezzo attuale dell'azione	€16.50
Massimo di 52 settimane	€18.50
Minimo di 52 settimane	€13.34
Beta	1.09
1Variazione di 1 mese	-7.82%
Variazione a 3 mesi	13.95%
Variazione di 1 anno	8.55%
3Variazione a 3 anni	-59.21%
Variazione a 5 anni	-2.94%
Variazione dall'IPO	111.57%

Notizie e aggiornamenti recenti

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

May 21

Recent updates

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

May 21

Are Medios' (ETR:ILM1) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Bullish: Analysts Just Made A Significant Upgrade To Their Medios AG (ETR:ILM1) Forecasts

Jan 21

What You Need To Know About Medios AG's (ETR:ILM1) Investor Composition

Jan 19

Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Dec 24

Analysts Are Betting On Medios AG (ETR:ILM1) With A Big Upgrade This Week

Dec 09

The Medios (ETR:ILM1) Share Price Is Up 128% And Shareholders Are Boasting About It

Dec 08

Medios AG's (ETR:ILM1) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 22

What Can We Make Of Medios AG’s (ETR:ILM1) High Return On Capital?

Jun 22

Rendimenti per gli azionisti

	ILM1	DE Healthcare	DE Mercato
7D	-7.9%	3.1%	3.3%
1Y	8.6%	-2.0%	4.7%

Ritorno vs Industria: ILM1 ha superato il German Healthcare che ha restituito -2 % nell'ultimo anno.

Rendimento vs Mercato: ILM1 ha superato il mercato German che ha restituito 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ILM1's price volatile compared to industry and market?
ILM1 volatility
ILM1 Average Weekly Movement	5.8%
Healthcare Industry Average Movement	3.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.6%

Prezzo delle azioni stabile: ILM1 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di ILM1 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2016	1,011	Matthias Gaertner	www.medios.ag

Medios AG, insieme alle sue controllate, fornisce specialità farmaceutiche principalmente in Germania. Opera attraverso i segmenti Fornitura farmaceutica e Terapie specifiche per il paziente. Il segmento Fornitura farmaceutica offre prodotti per oncologia, neurologia, autoimmunologia, oftalmologia, infettivologia ed emofilia.

Medios AG Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Medios con la sua capitalizzazione di mercato?
ILM1 statistiche fondamentali
Capitalizzazione di mercato	€420.92m
Guadagni(TTM)	€15.95m
Ricavi(TTM)	€1.84b

26.4x

Rapporto P/E

0.2x

Rapporto P/S

ILM1 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ILM1 Conto economico (TTM)
Ricavi	€1.84b
Costo del fatturato	€1.72b
Profitto lordo	€113.72m
Altre spese	€97.77m
Guadagni	€15.95m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 12, 2024

Utile per azione (EPS)	0.63
Margine lordo	6.19%
Margine di profitto netto	0.87%
Rapporto debito/patrimonio netto	0.03%

Come si è comportato ILM1 nel lungo periodo?

Vedi performance storica e confronto

ILM1 Panoramica delle azioni

Premi

Analisi del rischio

Medios AG Concorrenti

HMSE:HAEK

€85.2m

XTRA:M12

€265.6m

XTRA:RHK

€783.2m

XTRA:SBS

€531.8m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 12% to €32.40

Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Recent updates

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 12% to €32.40

Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First quarter 2024 earnings released: EPS: €0.17 (vs €0.20 in 1Q 2023)

Price target decreased by 14% to €34.60

Full year 2023 earnings: EPS and revenues miss analyst expectations

Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.

Investor sentiment improves as stock rises 21%

Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.

Medios AG, Annual General Meeting, Jun 26, 2024

Medios AG to Report Q2, 2024 Results on Aug 13, 2024

Price target decreased by 19% to €34.25

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Medios AG to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.21 in 2Q 2022)

First quarter 2023 earnings released: EPS: €0.20 (vs €0.21 in 1Q 2022)

Full year 2022 earnings released: EPS: €0.77 (vs €0.37 in FY 2021)

Price target decreased by 7.4% to €42.40

Is Medios AG (ETR:ILM1) Trading At A 39% Discount?

Medios AG to Report First Half, 2023 Results on Aug 14, 2023

Investor sentiment improved over the past week

Is Medios (ETR:ILM1) Using Too Much Debt?

Medios AG (XTRA:ILM1) entered into a purchase agreement to acquire Blisterzentrum Baden-Württemberg Gmbh.

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to €45.80

Third quarter 2022 earnings: EPS exceeds analyst expectations

Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?

Investor sentiment deteriorated over the past week

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is Medios (ETR:ILM1) Using Too Much Debt?

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €54.80

Investor sentiment deteriorated over the past week

Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock

What Does Medios AG's (ETR:ILM1) Share Price Indicate?

Medios AG Provides Earnings Guidance for the Fiscal Year 2022

Consensus forecasts updated

Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet

Medios AG (XTRA:ILM1) entered into an agreement to acquire NewCo Pharma GmbH.

Price target increased to €51.75

Third quarter 2021 earnings released: EPS €0.18 (vs €0.07 in 3Q 2020)

Is There Now An Opportunity In Medios AG (ETR:ILM1)?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS €0.17 (vs €0.06 in 2Q 2020)

Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price

What Is Medios AG's (ETR:ILM1) Share Price Doing?

First quarter 2021 earnings released: EPS €0.15 (vs €0.15 in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: EPS €0.39 (vs €0.67 in FY 2019)

Medios AG Reiterates Revenue Guidance for the Financial Year 2021

New 90-day low: €34.80